Literature DB >> 28520967

In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.

Christopher C Nixon1, Maud Mavigner2, Guido Silvestri3, J Victor Garcia1.   

Abstract

Current HIV therapy is not curative regardless of how soon after infection it is initiated or how long it is administered, and therapy interruption almost invariably results in robust viral rebound. Human immunodeficiency virus persistence is therefore the major obstacle to a cure for AIDS. The testing and implementation of novel yet unproven approaches to HIV eradication that could compromise the health status of HIV-infected individuals might not be ethically warranted. Therefore, adequate in vitro and in vivo evidence of efficacy is needed to facilitate the clinical implementation of promising strategies for an HIV cure. Animal models of HIV infection have a strong and well-documented history of bridging the gap between laboratory discoveries and eventual clinical implementation. More recently, animal models have been developed and implemented for the in vivo evaluation of novel HIV cure strategies. In this article, we review the recent progress in this rapidly moving area of research, focusing on the two most promising model systems: humanized mice and nonhuman primates.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  AIDS; HIV latency; animal models; humanized mice; non-human primates.

Mesh:

Substances:

Year:  2017        PMID: 28520967      PMCID: PMC5410984          DOI: 10.1093/infdis/jiw637

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  146 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency.

Authors:  Anding Shen; Hung-Chih Yang; Yan Zhou; Amanda J Chase; Jean D Boyer; Hao Zhang; Joseph B Margolick; M Christine Zink; Janice E Clements; Robert F Siliciano
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

5.  Follicular dendritic cells and human immunodeficiency virus infectivity.

Authors:  S L Heath; J G Tew; J G Tew; A K Szakal; G F Burton
Journal:  Nature       Date:  1995-10-26       Impact factor: 49.962

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year.

Authors:  Bradford K Berges; Sarah R Akkina; Leila Remling; Ramesh Akkina
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

8.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

9.  Graft versus host disease in the bone marrow, liver and thymus humanized mouse model.

Authors:  Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

10.  Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.

Authors:  Morgan L Chateau; Paul W Denton; Michael D Swanson; Ian McGowan; J Victor Garcia
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more
  20 in total

Review 1.  Brain PET Imaging: Value for Understanding the Pathophysiology of HIV-associated Neurocognitive Disorder (HAND).

Authors:  Sanhita Sinharay; Dima A Hammoud
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

2.  Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Authors:  Matthew M Hernandez; Audrey Fahrny; Ravi Sachidanandam; Roberto F Speck; Viviana Simon; Anitha Jayaprakash; Gustavo Gers-Huber; Marsha Dillon-White; Annette Audigé; Lubbertus C F Mulder
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  The Establishment of an In Vivo HIV-1 Infection Model in Humanized B-NSG Mice.

Authors:  Tian-Jiao Fan; Li Sun; Xian-Guang Yang; Xia Jin; Wei-Wei Sun; Jian-Hua Wang
Journal:  Virol Sin       Date:  2019-12-21       Impact factor: 4.327

4.  μ-Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies.

Authors:  Hannah S Sperber; Padma Priya Togarrati; Kyle A Raymond; Mohamed S Bouzidi; Renata Gilfanova; Alan G Gutierrez; Marcus O Muench; Satish K Pillai
Journal:  FASEB J       Date:  2020-09-09       Impact factor: 5.191

5.  Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency.

Authors:  Gideon Wolf; Nevil J Singh
Journal:  Viral Immunol       Date:  2021-02-17       Impact factor: 2.175

Review 6.  The Contributions of Clinical Pharmacology to HIV Cure Research.

Authors:  Courtney V Fletcher; Shetty Ravi Dyavar; Arpan Acharya; Siddappa N Byrareddy
Journal:  Clin Pharmacol Ther       Date:  2021-04-18       Impact factor: 6.903

7.  Tracking Human Immunodeficiency Virus-1 Infection in the Humanized DRAG Mouse Model.

Authors:  Jiae Kim; Kristina K Peachman; Ousman Jobe; Elaine B Morrison; Atef Allam; Linda Jagodzinski; Sofia A Casares; Mangala Rao
Journal:  Front Immunol       Date:  2017-10-27       Impact factor: 7.561

Review 8.  Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.

Authors:  Guido Ferrari; Justin Pollara; Georgia D Tomaras; Barton F Haynes
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 9.  Human Immune System Mice for the Study of Human Immunodeficiency Virus-Type 1 Infection of the Central Nervous System.

Authors:  Teresa H Evering; Moriya Tsuji
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

10.  HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo.

Authors:  Zhengtao Jiang; Huitong Liang; Hanyu Pan; Yue Liang; Hua Wang; Xinyi Yang; Panpan Lu; Xiao Zhang; Jinlong Yang; Dengji Zhang; Xiaoting Shen; Jing Wang; Zhiming Liang; Qinru Lin; Yanan Wang; Lin Zhao; Yangcheng Zhong; Hongzhou Lu; Huanzhang Zhu
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.